CMV Infection and Reactivation

  • Stefan Schneeberger
  • Raimund Margreiter
  • Stefano Lucchina
  • Marco Lanzetta
  • Hugo Bonatti


Herpes virus infections are common causes of morbidity and mortality in solid organ and haematopoietic stem cell transplant recipients. Recent innovations in diagnosis, prophylaxis and treatment have reduced the incidence of herpes virus infections during the early posttransplant period, but they continue to significantly influence the outcome after transplantation [1].


Human Leukocyte Antigen Acute Rejection Rejection Episode Human Papilloma Virus Preemptive Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Razonable RR (2005) Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 62[Suppl. 1]:7–13Google Scholar
  2. 2.
    Rosenthal SL, Stanberry LR, Biro FM et al (1997) Seroprevalence of herpes simplex virus types 1 and 2 and cytomegalovirus in adolescents. Clin Infect Dis 24:135–139PubMedGoogle Scholar
  3. 3.
    Paya CV (1999) Indirect effects of CMV in the solid organ transplant patient. Transpl Infect Dis 1[Suppl. 1]:8–12PubMedGoogle Scholar
  4. 4.
    Evans PC, Soin A, Wreghitt TG et al (2000) An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation 69:30–35PubMedCrossRefGoogle Scholar
  5. 5.
    De Otero J, Gavalda J, Murio E et al (1998) Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation. Clin Infect Dis 26:865–870PubMedGoogle Scholar
  6. 6.
    Hebart H, Einsele H (1998) Diagnosis and treatment of cytomegalovirus infection. Curr Opin Hematol 5:483–487PubMedCrossRefGoogle Scholar
  7. 7.
    Hibberd PL, Snydman DR (1995) Cytomegalovirus infection in organ transplant recipients. Infect Dis Clin North Am 9:863–877PubMedGoogle Scholar
  8. 8.
    Snydman DR (1999) Infection in solid organ transplantation. Transpl Infect Dis 1:21–28PubMedCrossRefGoogle Scholar
  9. 9.
    Rubin RH, Ikonen T, Gummert JF et al (1999) The therapeutic prescriptions for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies. Transpl Infect Dis 1:29–39PubMedCrossRefGoogle Scholar
  10. 10.
    Jones JW, Gruber SA, Barker JH et al (2000) Successful hand transplantation. One-year follow-up. Louisville Hand Transplant Team. N Engl J Med 343:468–473PubMedCrossRefGoogle Scholar
  11. 11.
    Margreiter R, Brandacher G, Ninkovic M et al (2002) A double-hand transplant can be worth the effort! Transplantation 74:85–90PubMedCrossRefGoogle Scholar
  12. 12.
    Dubernard JM, Petruzzo P, Lanzetta M et al (2003) Functional results of the first human double-hand transplantation. Ann Surg 238:128–136PubMedCrossRefGoogle Scholar
  13. 13.
    Lanzetta M, Petruzzo P, Margreiter R et al (2005) The International Registry on Hand and Composite Tissue Transplantation. Transplantation 79:1210–1214PubMedCrossRefGoogle Scholar
  14. 14.
    Schneeberger S, Zelger B, Ninkovic M et al (2005) Transplantation of the hand. Transplant Rev 19:100–107CrossRefGoogle Scholar
  15. 15.
    Schneeberger S, Ninkovic M, Piza-Katzer H et al (2006) Status 5 years after bilateral hand transplantation. Am J Transpl 6:834–841CrossRefGoogle Scholar
  16. 16.
    Schneeberger S, Kreczy A, Brandacher G et al (2004) Steroid-and ATG-resistant rejection after forearm transplantation responds to Campath-1H. Am J Transplant 4:1372–1374PubMedCrossRefGoogle Scholar
  17. 17.
    Schneeberger S, Lucchina S, Lanzetta M et al (2005) Cytomegalovirus-related complications in human hand transplantation. Transplantation 80:441–447PubMedCrossRefGoogle Scholar
  18. 18.
    Hofmann GO, Kirschner MH (2000) Clinical experience in allogeneic vascularized bone and joint allografting. Microsurgery 20:375–383PubMedCrossRefGoogle Scholar
  19. 19.
    Villacian JS, Paya CV (1999) Prevention of infections in solid organ transplant recipients. Transpl Infec Dis 1:50–64CrossRefGoogle Scholar
  20. 20.
    Kurz S, Steffens HP, Mayer A et al (1997) Latency versus persistence or intermittent recurrences: evidence for a latent state of murine cytomegalovirus in the lungs. J Virol 71:2980–2987PubMedGoogle Scholar
  21. 21.
    Benz C, Utermohlen O, Wulf A et al (2002) Activated virus-specific T cells are early indicators of anti-CMV immune reactions in liver transplant patients. Gastroenterology 122:1201–1215PubMedCrossRefGoogle Scholar
  22. 22.
    Papanicolaou GA, Latouche JB, Tan C et al (2003) Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele. Blood 102:2498–2505PubMedCrossRefGoogle Scholar
  23. 23.
    Solache A, Morgan CL, Dodi AI et al (1999) Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. J Immunol 163:5512–5518PubMedGoogle Scholar
  24. 24.
    Maecker HT, Maino VC (2004) Analyzing T-cell responses to cytomegalovirus by cytokine flow cytometry. Hum Immunol 65:493–499PubMedCrossRefGoogle Scholar
  25. 25.
    ten Berge IJ, Gamadia LE, Remmerswaal EB et al (2001) Differentiation of CMV-specific CD8(POS) T lymphocytes in primary CMV infection after renal transplantation. Transplant Proc 33:3630PubMedCrossRefGoogle Scholar
  26. 26.
    Trautmann L, Rimbert M, Echasserieau K et al (2005) Selection of T cell clones expressing high-affinity public TCRs within human cytomegalovirus-specific CD8 T cell responses. J Immunol 175:6123–6132PubMedGoogle Scholar
  27. 27.
    Gamadia LE, Remmerswaal EB, Surachno S et al (2004) Cross-reactivity of cytomegalovirus-specific CD8+ T cells to allo-major histocompatibility complex class I molecules. Transplantation 77:1879–1885PubMedCrossRefGoogle Scholar
  28. 28.
    Hove WR, van Hoek B, Bajema IM et al (2003) Extensive chimerism in liver transplants: vascular endothelium, bile duct epithelium, and hepatocytes. Liver Transpl 9:552–556PubMedCrossRefGoogle Scholar
  29. 29.
    Hebart H, Kanz L, Jahn G et al (1998) Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects. Drugs 55:59–72PubMedCrossRefGoogle Scholar
  30. 30.
    Barrett-Muir WY, Aitken C, Templeton K et al (1998) Evaluation of the murex hybrid capture cytomegalovirus DNA assay versus plasma PCR and shell vial assay for diagnosis of human cytomegalovirus viremia in immunocompromised patients. J Clin Microbiol 36:2554–2556PubMedGoogle Scholar
  31. 31.
    Ljungman P, Griffiths P, Paya C (2002) Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34:1094–1097PubMedCrossRefGoogle Scholar
  32. 32.
    Singh N, Wannstedt C, Keyes L et al (2005) Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 79:85–90PubMedCrossRefGoogle Scholar
  33. 33.
    Hart GD, Paya CV (2001) Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 11:73–81PubMedCrossRefGoogle Scholar
  34. 34.
    Faulds D, Heel RC (1990) Ganciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 39:597–638PubMedGoogle Scholar
  35. 35.
    Limaye AP, Corey L, Koelle DM et al (2000) Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356:645–649PubMedCrossRefGoogle Scholar
  36. 36.
    Gane E, Saliba F, Valdecasas GJ et al (1997) Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet 350:1729–1733PubMedCrossRefGoogle Scholar
  37. 37.
    Wiltshire H, Paya CV, Pescovitz MD et al (2005) Valganciclovir Solid Organ Transplant Study Group. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 79:1477–1483PubMedCrossRefGoogle Scholar
  38. 38.
    Akalin E, Sehgal V, Ames S et al (2003) Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 3:731–735PubMedCrossRefGoogle Scholar
  39. 39.
    Valantine HA, Luikart H, Doyle R et al (2001) Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 72:1647–1652PubMedCrossRefGoogle Scholar
  40. 40.
    Chrisp P, Clissold SP (1991) Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41:104–129PubMedGoogle Scholar
  41. 41.
    De Clercq E (1993) Therapeutic potential of HPMPC as an antiviral drug. Rev Med Virol 3:85–96CrossRefGoogle Scholar
  42. 42.
    Falagas ME, Paya C, Ruthazer R et al (1998) Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis. Transplantation 66:1020–1028PubMedCrossRefGoogle Scholar
  43. 43.
    Schnitzler MA, Woodward RS, Brennan DC et al (1997) The effects of cytomegalovirus serology on graft and recipient survival in cadaveric renal transplantation: implications for organ allocation. Am J Kidney Dis 29:428–434PubMedGoogle Scholar
  44. 44.
    Schneeberger H, Aydemir S, Muller R et al (2000) Hyperimmunoglobulin prophylaxis, monitoring and preemptive ganciclovir treatment eliminate the risk of CMV infection to improve patient and renal allograft survival. Transpl Int 13[Suppl. 1]:354CrossRefGoogle Scholar
  45. 45.
    Engstrand M, Lidehall AK, Totterman TH et al (2003) Cellular responses to cytomegalovirus in immunosuppressed patients: circulating CD8+ T cells recognizing CMVpp65 are present but display functional impairment. Clin Exp Immunol 132:96–104PubMedCrossRefGoogle Scholar
  46. 46.
    Nachbaur D, Bonatti H, Oberaigner W et al (2001) Survival after bone marrow transplantation from cytomegalovirus seropositive sibling donors. Lancet 358:1157–1159PubMedCrossRefGoogle Scholar
  47. 47.
    Fateh-Moghadam S, Bocksch W, Wessely R et al (2003) Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation 76:1470–1474PubMedCrossRefGoogle Scholar
  48. 48.
    Streblow DN, Kreklywich C, Yin Q et al (2003) Cytomegalovirus-mediated upregulation of chemokine expression correlates with the acceleration of chronic rejection in rat heart transplants. J Virol 77:2182–2194PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2007

Authors and Affiliations

  • Stefan Schneeberger
    • 1
  • Raimund Margreiter
    • 2
  • Stefano Lucchina
    • 3
  • Marco Lanzetta
    • 4
    • 5
    • 6
    • 7
    • 8
  • Hugo Bonatti
    • 1
  1. 1.Department of General and Transplant SurgeryMedical UniversityInnsbruckAustria
  2. 2.Department of Transplant SurgeryThe Medical UniversityInnsbruckAustria
  3. 3.Hand Surgery and Microsurgery UnitSan Gerardo HospitalMonza, MilanItaly
  4. 4.Italian Institute of Hand SurgeryMonza, MilanItaly
  5. 5.Hand Surgery and Reconstructive Microsurgery UnitSan Gerardo HospitalMonza, MilanItaly
  6. 6.University of Milan-BicoccaMilanItaly
  7. 7.University of CanberraAustralia
  8. 8.International Hand and CompositeTissue Allograft SocietyAustralia

Personalised recommendations